Drug Search Results
More Filters [+]

Ruxolitinib

Alternative Names: ruxolitinib, incb018424, jakavi, jakafi, inc 424, inc424, inc-424, opzelura
Latest Update: 2024-10-26
Latest Update Note: Clinical Trial Update

Product Description

Ruxolitinib is in a class of medications called kinase inhibitors. It works to treat myelofibrosis and PV by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells. It works to treat GVHD by blocking the signals of the cells that cause GVHD.

Mechanisms of Action: JAK1 Inhibitor,JAK2 Inhibitor,STAT Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Myelofibrosis | Polycythemia | Thrombocythemia, Essential | Polycythemia Vera | Dermatitis | Dermatitis, Atopic | Vitiligo

Known Adverse Events: Dizziness | Headache | Anemia | Thrombocytopenia | Dermatitis | Erythema | Folliculitis | Urticaria | Nasopharyngitis | Pharyngitis | Tonsillitis | Dermatitis, Atopic | Pruritus | Vitiligo | Bronchitis | Diarrhea

Company: Incyte
Company Location: WILMINGTON DE 19803
Company CEO: Hervé Hoppenot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ruxolitinib

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Korea, Malaysia, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 119

Highest Development Phases

Phase 3: Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Anemia|Dermatitis, Atopic|Graft vs Host Disease|Myelodysplastic Syndrome|Myelofibrosis|Neurodermatitis|Polycythemia Vera|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Prurigo|Thrombocythemia, Essential|Thrombocytosis|Thrombosis|Vitiligo

Phase 2: Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Adenocarcinoma|Blast Crisis|Breast Cancer|Breast Diseases|Bronchiolitis Obliterans|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Clear Cell Adenocarcinoma|Colorectal Cancer|Dermatitis|Dermatitis, Seborrheic|Ductal Breast Carcinoma|Ductal Carcinoma|Endometrioid Carcinoma|Eosinophilia|Exanthema|Fallopian Tube Cancer|Head and Neck Cancer|Hepatitis B, Chronic|Hepatomegaly|Hidradenitis Suppurativa|Hodgkin Lymphoma|Hypereosinophilic Syndrome|Inflammatory Breast Cancer|Intraductal Noninfiltrating Carcinoma|Juvenile Myelomonocytic Leukemia,|Lichen Planus|Lichen Sclerosus et Atrophicus|Lobular Carcinoma|Lung Cancer|Lupus Erythematosus, Discoid|Lupus Erythematosus, Systemic|Lymphohistiocytosis, Hemophagocytic|Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Multiple Myeloma|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myeloproliferative Disorders|Ovarian Cancer|Pancreatic Cancer|Peritoneal Cancer|Prostate Cancer|Serous Cystadenocarcinoma|Skin Manifestations|Squamous Cell Carcinoma

Phase 1: Cachexia|Cytokine Release Syndrome|Healthy Volunteers|Non-Small-Cell Lung Cancer|Oncology Unspecified|Pancreatic Ductal Carcinoma|Wasting Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TRANSFORM-2

P3

Active, not recruiting

Myelofibrosis

2031-11-25

HEM-iSMART C

P2

Not yet recruiting

Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, Non-Hodgkin

2031-10-01

2020-002071-35

P2

Active, not recruiting

Myelofibrosis

2030-10-26

INCB18424-370

P3

Not yet recruiting

Graft vs Host Disease

2030-10-20

Recent News Events